Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1843842
                    [Title] => Febuxostat prevented early gout flares
                    [Summary] => The urate-lowering therapy febuxostat reduced the number of disease flares that the people with early gout experienced, relative to placebo, in a double-blind study.
                    [DatePublished] => 2018-08-19 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 1
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 617159
                    [Title] => New agents for gout provide alternatives to allopurinol
                    [Summary] => 
The likely approval of febuxostat for the treatment of gout means that there soon will be an alternative for the underserved group of patients with severe disease who cannot tolerate allopurinol.
                    [DatePublished] => 2010-10-03 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

Febuxostat

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1843842
                    [Title] => Febuxostat prevented early gout flares
                    [Summary] => The urate-lowering therapy febuxostat reduced the number of disease flares that the people with early gout experienced, relative to placebo, in a double-blind study.
                    [DatePublished] => 2018-08-19 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 1
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 617159
                    [Title] => New agents for gout provide alternatives to allopurinol
                    [Summary] => 
The likely approval of febuxostat for the treatment of gout means that there soon will be an alternative for the underserved group of patients with severe disease who cannot tolerate allopurinol.
                    [DatePublished] => 2010-10-03 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

Febuxostat prevented early gout flares

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | August 19, 2018 - 12:00am

The urate-lowering therapy febuxostat reduced the number of disease flares that the people with early gout experienced, relative to placebo, in a double-blind study.

Opinion

New agents for gout provide alternatives to allopurinol

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | October 3, 2010 - 12:00am

The likely approval of febuxostat for the treatment of gout means that there soon will be an alternative for the underserved group of patients with severe disease who cannot tolerate allopurinol.

Opinion